Basal Insulin Analogs Class Overview Monograph

What Are Basal Insulin Analogs?

Basal insulin analogs are recombinant human insulin molecules with amino-acid modifications or formulation changes that extend their absorption from a subcutaneous depot. Unlike NPH insulin, which has a pronounced peak around 4-8 hours, approved analogs produce relatively flat serum profiles across 18-42 hours. This flatter profile reduces nocturnal hypoglycemia risk and allows once-daily dosing for most patients.

The class spans four distinct molecular entities in current U.S. Clinical use, each with a separate pharmacokinetic signature. Prescribers who understand those differences can match the right analog to each patient's lifestyle, renal function, and hypoglycemia risk tolerance.

Historical Context

NPH insulin dominated basal coverage for decades, but its peak activity and twice-daily requirement created both hypoglycemia and adherence problems. Insulin glargine U-100 (Lantus) received FDA approval in April 2000, offering a genuinely peakless 24-hour profile for the first time. Insulin detemir (Levemir) followed in 2005, and insulin degludec (Tresiba) was approved in September 2015 with the longest duration of any approved basal agent.

Biosimilar Field

Glargine U-100 now has three FDA-approved biosimilars in the United States: Basaglar (approved 2015), Semglee (interchangeable designation 2021), and Rezvoglar (approved 2022). The FDA's interchangeable biosimilar designation for Semglee means pharmacists may substitute it without a new prescription in most states, a consideration for prior-authorization workflows.

Pharmacology and Mechanism of Action

All basal analogs act at the insulin receptor, a transmembrane tyrosine kinase. Receptor activation drives GLUT4 translocation in muscle and adipose tissue, suppresses hepatic glucose production, and promotes glycogen synthesis. What distinguishes analogs from human insulin is how long they maintain those receptor signals after subcutaneous injection.

Glargine U-100 and U-300

Glargine carries two arginine residues added to the B-chain C-terminus and an asparagine-to-glycine substitution at A21. These changes shift the isoelectric point to pH 6.7. At physiologic subcutaneous pH the molecule precipitates, forming microcrystals that dissolve slowly over approximately 24 hours. PubMed pharmacokinetic studies confirm a flat, peakless profile with duration of action averaging 20-24 hours in T2D.

Glargine U-300 (Toujeo) compresses the same glargine molecule into a 300 units/mL formulation. The smaller injection volume creates a more compact depot with slower surface-area-to-volume dissolution, extending duration to approximately 36 hours and reducing within-day variability compared with U-100. A crossover pharmacokinetic study (N=30) published in Diabetes Care showed significantly lower intraday variability for U-300 versus U-100 (CV 20% vs 28%, P<0.01).

Insulin Detemir

Detemir attaches a 14-carbon fatty acid chain (myristic acid) at LysB29 and removes ThrB30. The fatty acid enables reversible albumin binding in the subcutaneous tissue and plasma, creating a buffering depot. Approximately 98-99% of circulating detemir is albumin-bound, extending its half-life. PubMed data show duration of 18-24 hours dose-dependently, meaning some patients require twice-daily dosing at lower doses.

Insulin Degludec

Degludec removes ThrB30, adds a hexadecanedioic fatty acid to LysB29 via a glutamic acid linker, and self-assembles into soluble multi-hexamers in the subcutaneous space. These multi-hexamers dissociate in a slow, steady manner. The pharmacokinetic profile in NEJM-published data shows a half-life of approximately 25 hours and steady-state duration exceeding 42 hours, making it the longest-acting approved basal insulin. Coefficient of variation for day-to-day glucose-lowering effect is roughly 20% for degludec versus approximately 43% for glargine U-100 in head-to-head PK studies.

Approved Indications and Patient Selection

Type 1 Diabetes

All four analogs are approved for T1D. Degludec and glargine U-300 offer the flattest profiles, which matter most in T1D where total daily doses are lower and hypoglycemia risk per unit is higher. ADA Standards of Care 2024 (Section 9) state: "Basal insulin analogs (long-acting insulin analogs) have been shown to reduce rates of nocturnal hypoglycemia compared to NPH insulin in patients with type 1 diabetes."

Type 2 Diabetes

In T2D, basal insulin is typically initiated when A1C remains above target after maximizing non-insulin agents. The American Diabetes Association and the American Association of Clinical Endocrinology recommend a starting dose of 10 units per day or 0.1-0.2 units/kg/day, titrated upward by 2 units every 3 days until fasting glucose is 80-130 mg/dL. AACE/ACE 2023 guidelines place basal insulin as a tier-2 intensification option after GLP-1 receptor agonists in patients without cardiovascular disease.

Pediatric Approvals

Glargine U-100 is approved in children aged 6 years and older with T1D. Degludec holds approval down to age 1 year for T1D. FDA prescribing information for Tresiba notes the pediatric approval for T1D and T2D at age 1 year and older. Detemir is approved from age 2 years. Glargine U-300 does not have a pediatric approval as of July 2025.

Key Clinical Trials

ORIGIN Trial (Glargine U-100)

ORIGIN (N=12,537) randomized people with dysglycemia and established cardiovascular risk to insulin glargine U-100 or standard care. Published in NEJM (2012), ORIGIN showed no significant difference in the primary composite cardiovascular endpoint (HR 1.02, 95% CI 0.94-1.11) over a median of 6.2 years. Glargine was cardiovascularly neutral. Median A1C in the glargine group was 6.5% versus 6.8% in the comparator group, with a mean weight gain of 1.6 kg.

DEVOTE Trial (Degludec vs. Glargine U-100)

DEVOTE (N=7,637) compared degludec versus glargine U-100 in T2D patients with high cardiovascular risk in a double-blind cardiovascular outcomes trial. Published in NEJM (2017), DEVOTE demonstrated non-inferiority for the primary MACE endpoint (HR 0.91, 95% CI 0.78-1.06). Severe hypoglycemia occurred in 4.9% of the degludec group versus 6.6% of the glargine group (HR 0.60, P<0.001), a 40% relative risk reduction. Nocturnal severe hypoglycemia was 53% lower with degludec.

EDITION Program (Glargine U-300)

The EDITION series comprised six phase-3 trials comparing glargine U-300 (Toujeo) with glargine U-100 (Lantus) in T1D and T2D. EDITION 1 (N=807, T2D on basal-bolus) showed non-inferior A1C reduction at 26 weeks (mean difference 0.00%, 95% CI -0.11 to 0.11%) with a statistically significant reduction in nocturnal confirmed or severe hypoglycemia (RR 0.69, P<0.001) during weeks 1-8. EDITION 4 (N=549, T1D) showed similar A1C control with a 21% lower rate of any nocturnal confirmed hypoglycemia (P=0.023).

BEGIN ONCE LONG (Degludec in T1D)

BEGIN ONCE LONG (N=629) randomized T1D adults to degludec once daily versus glargine U-100 once daily in a 52-week open-label trial. A1C reductions were equivalent (both -0.4%). Nocturnal confirmed hypoglycemia was 25% lower with degludec (rate ratio 0.75, P=0.021). This trial directly supported the T1D FDA approval for degludec.

Cardiovascular Safety of Detemir

Detemir lacks a dedicated cardiovascular outcomes trial, but a large meta-analysis in Diabetes Care (N=6,426 across 9 trials) found no signal of increased cardiovascular events versus comparators over trial periods of 6 months to 3 years.

Dosing and Titration

Starting Doses

Basal insulin initiation should be tailored to the clinical scenario:

• T2D insulin-naive: 10 units subcutaneous once daily (or 0.1-0.2 units/kg/day), typically at bedtime or the same time each day.
• T1D transitioning from NPH: convert the total NPH dose to 80% of that dose as a basal analog to reduce hypoglycemia risk during transition.
• Hospitalized patients: institution-specific protocols apply; avoid sliding-scale-only regimens per SHM/AACE inpatient guidelines.

Titration Protocol

The most evidence-based self-titration protocol for T2D is the "Treat-to-Target" algorithm: increase the basal dose by 2 units every 3 days if the average fasting self-monitored glucose over the prior 3 days exceeds 130 mg/dL. The Treat-to-Target trial (N=756) demonstrated that patients using this 3-day rule achieved A1C below 7% in 58% of the glargine group versus 38% of the NPH group at 24 weeks.

Timing Flexibility with Degludec

Degludec's ultra-long duration allows flexible once-daily dosing. A phase-3 trial (N=687) demonstrated that degludec dosed flexibly (rotating between morning and evening on alternating days, creating intervals of 8-40 hours) was non-inferior to degludec dosed at a fixed time, with equivalent hypoglycemia rates. This is not replicated for glargine or detemir, where fixed-time daily dosing is recommended.

Dose Conversion Between Agents

When switching from glargine U-100 to glargine U-300, a unit-for-unit conversion is used, but patients may require a 10-18% higher total daily dose because U-300 has approximately 90% the bioavailability of U-100 on a unit-per-unit basis at steady state. FDA labeling for Toujeo confirms that the doses are not directly interchangeable on a unit-per-unit basis.

When converting from any basal analog to degludec, a unit-for-unit switch is generally well-tolerated in T2D. In T1D, starting degludec at 80% of the prior basal dose with subsequent upward titration reduces the risk of early hypoglycemia.

Adverse Effects and Safety

Hypoglycemia

Hypoglycemia is the most clinically significant adverse effect of the entire class. Nocturnal hypoglycemia carries additional risk because patients may not self-correct promptly. Across the class hierarchy by nocturnal hypoglycemia risk (lowest to highest): degludec < glargine U-300 < glargine U-100 ≈ detemir > NPH. The DEVOTE sub-study (DEVOTE 3) linked severe hypoglycemia episodes to increased subsequent cardiovascular events and mortality, reinforcing the clinical importance of minimizing severe hypoglycemia in high-risk patients.

Weight Gain

All basal insulins produce weight gain proportional to the anabolic effect of insulin. Detemir has consistently shown less weight gain than glargine in head-to-head T2D trials. A meta-analysis in Lancet (2004-2009 data, N=2,250) showed detemir associated with approximately 1 kg less weight gain versus NPH and similar or slightly less than glargine. Weight gain can be attenuated by co-prescribing a GLP-1 receptor agonist.

Injection-Site Reactions

Lipoatrophy and lipohypertrophy occur with any subcutaneous insulin. Rotating injection sites across the abdomen, thigh, and upper arm reduces the risk. Lipohypertrophy impairs absorption unpredictably and is the most common cause of unexplained glycemic variability in T1D patients on long-standing insulin therapy.

Renal and Hepatic Dosing Considerations

No dose adjustment is required based on renal function for any basal analog, but dose reduction may be necessary as GFR declines because gluconeogenesis decreases (reducing counter-regulatory capacity) and insulin clearance slows. ADA Standards 2024 (Section 4) recommend increased self-monitoring frequency and smaller titration steps in patients with CKD stage 3b or worse.

Drug Interactions

Basal insulins have no cytochrome P450-mediated interactions. Clinically relevant pharmacodynamic interactions include:

• Additive hypoglycemia: sulfonylureas, meglitinides, alcohol, salicylates at high doses, MAO inhibitors, beta-blockers (also mask symptoms), quinolones (ciprofloxacin documented with sulfonylureas, lesser direct insulin effect).
• Hyperglycemia: corticosteroids, atypical antipsychotics (olanzapine, clozapine), thiazide diuretics, protease inhibitors, sympathomimetics. Patients starting high-dose corticosteroids may require 20-50% basal dose increases and addition of a correction bolus.
• Beta-blockers: both mask tachycardia as a hypoglycemia symptom and can prolong hypoglycemia by inhibiting glycogenolysis. FDA drug interaction guidance lists beta-blockers among agents that modify insulin requirements.

Monitoring Parameters

The following monitoring framework applies to any patient on a basal insulin analog:

Glycemic targets (ADA 2024):

• Fasting glucose: 80-130 mg/dL
• A1C <7% in most non-pregnant adults; <8% acceptable in patients with hypoglycemia unawareness, limited life expectancy, or advanced complications

Frequency of A1C testing:

• Every 3 months until target achieved, then every 6 months once stable. ADA recommends point-of-care A1C when real-time results will change management.

CGM vs. SMBG:

• Time-in-Range (TIR 70-180 mg/dL) greater than 70% correlates with A1C below 7% and is the preferred metric when CGM is available. An ADA/EASD consensus report (2019) established CGM-derived TIR as a validated endpoint in clinical trials.

Renal function: Check eGFR and urine albumin-creatinine ratio annually. Declining eGFR below 45 mL/min/1.73m2 should prompt dose conservatism and increased hypoglycemia monitoring.

Body weight and lipids: Annual assessment. Patients gaining more than 3 kg over 6 months on basal insulin should be evaluated for co-prescription of a GLP-1 receptor agonist or SGLT2 inhibitor.

Place in Therapy and Comparative Summary

Head-to-Head Comparisons

| Analog | Duration | Nocturnal Hypo Risk | CV Outcomes Data | Weight Gain | |---|---|---|---|---| | Glargine U-100 | 20-24 h | Moderate | ORIGIN (neutral) | Moderate | | Glargine U-300 | ~36 h | Lower than U-100 | EDITION (safety only) | Similar to U-100 | | Detemir | 18-24 h | Similar to glargine U-100 | Meta-analysis (neutral) | Less than glargine | | Degludec | >42 h | Lowest in class | DEVOTE (non-inferior, fewer hypos) | Similar to glargine |

Selecting Among Agents

Degludec is the preferred choice when severe hypoglycemia risk is the dominant concern, particularly in T1D adults, elderly patients, and those with hypoglycemia unawareness. Endocrine Society Clinical Practice Guidelines (2022) state: "We suggest using insulin degludec or insulin glargine U-300 over insulin glargine U-100 or insulin detemir in adults with T2D who have frequent hypoglycemia or who require flexible dosing schedules."

Glargine U-100 biosimilars are appropriate first-line choices for cost-sensitive patients, those with adequate hypoglycemia awareness, and formulary-constrained settings. Detemir is an alternative where twice-daily dosing is acceptable and modest weight advantage is desirable. Glargine U-300 occupies a middle position: more coverage duration than U-100, single-device delivery, and established nocturnal hypoglycemia reduction, though without the full cardiovascular outcomes dataset of degludec.

Special Populations

Pregnancy

No basal insulin analog holds an FDA category A approval for pregnancy. NPH insulin has historically been the default given the longest safety record. ACOG Practice Bulletin 201 (2018, reaffirmed 2023) states NPH remains the standard basal agent during pregnancy. Glargine U-100 has accumulated substantial observational safety data, and some endocrinologists use it off-label in pregnancy when NPH is poorly tolerated, but strong randomized trial data in pregnancy are limited.

Older Adults

Older adults face amplified hypoglycemia consequences including falls, fractures, and cardiovascular events. ADA Standards 2024 Section 13 recommend an A1C target of <7.5-8% in healthy older adults and <8-9% in those with complex comorbidities, explicitly noting that basal insulin should be titrated conservatively to avoid hypoglycemia. Degludec's 40% lower severe hypoglycemia rate in DEVOTE makes it a reasonable first choice in this population.

Renal Impairment

Insulin requirements typically decrease as eGFR falls below 30 mL/min/1.73m2. All analogs are renally cleared to a degree. A pharmacokinetic study in Diabetes Care showed glargine clearance was modestly prolonged in severe renal impairment. Frequent glucose monitoring and a lower starting dose (reducing by 25-50% from the standard algorithm) are prudent in CKD stage 4-5.

Biosimilars: Prescribing and Substitution Considerations

The interchangeable biosimilar designation granted to Semglee (glargine-yfgn) in July 2021 was the first such designation for any insulin biosimilar in the United States. FDA guidance on interchangeable biosimilars specifies that an interchangeable product may be substituted by the pharmacist without prescriber intervention, though state laws vary.

Prescribers should counsel patients that biosimilar glargines are therapeutically equivalent to Lantus for A1C reduction and hypoglycemia profile. Switching between biosimilar glargines and the reference product mid-therapy does not require re-titration because the dose-response relationship is equivalent.

Rezvoglar (glargine-aglr) received FDA approval in December 2022 and began commercial availability in 2023, further reducing acquisition costs for payers and patients.

Patient Counseling Key Points

Patients starting a basal analog benefit from direct instruction on five areas:

1. Inject at the same time each day (except degludec, which allows flexible timing within an 8-40 hour window).
2. Rotate injection sites every dose. Use a finger-width distance from the prior injection site.
3. Store unopened pens/vials in the refrigerator (2-8°C). Once opened, store at room temperature below 30°C for up to 28 days (glargine, detemir) or 56 days (degludec).
4. Never dilute or mix basal analogs with other insulins in the same syringe.
5. Know hypoglycemia symptoms, carry 15 g of fast-acting carbohydrate, and apply the 15-15 rule: 15 g carbohydrate, recheck glucose in 15 minutes.

FDA MedWatch safety communications on insulin mix-ups highlight that look-alike/sound-alike errors between basal and bolus insulins remain a significant cause of preventable severe hypoglycemia.